FDA Warns Of Potential Safety Issues In Nephron Asthma Drug
The U.S. Food and Drug Administration issued a safety warning Monday over the potential health risks of Nephron Pharmaceuticals Corp.'s bronchial asthma drug Asthmanefrin, an over-the-counter inhaled solution that the agency...To view the full article, register now.
Already a subscriber? Click here to view full article